FDA Turns Down ATTR Cardiomyopathy Drug
(MedPage Today) -- CLEVELAND -- In a surprise Monday morning move, the FDA declined to expand the indication for anti-amyloid agent patisiran (Onpattro) in treating wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, or cardiac...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Cardiology | Cardiomyopathy | Heart | International Medicine & Public Health